VS-041 is currently being evaluated in a phase 1c trial in adult patients with heart failure with preserved ejection fraction and elevated serum levels of endotrophin. The Food and Drug Administration ...
Investigators from Foresee Pharmaceuticals Co. Ltd., Medical University of Vienna and Cleveland Clinic recently reported data on the effects of the matrix metalloproteinase-12 (MMP-12) inhibitor ...
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented 5-[2,7-diazaspiro[3.5]nonan-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives acting as matrix ...
"Given the lethal nature of GBM and the limited efficacy of current therapies, the application of TIMPs and their engineered minimal variants represents a novel and potentially transformative approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback